18F-FDG PET/CT can better assess bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma than can standard bone biopsy.
Examination with 18F-FDG PET/CT can better determine the level of bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) than can bone marrow biopsy, according to a study published in The Journal of Nuclear Medicine.
French researchers performed a retrospective study of 133 patients diagnosed with DLBCL between June 2005 and October 2011. To determine if there was bone marrow involvement, all the patients underwent whole-body 18F-FDG PET/CT and a bone marrow biopsy from the iliac crest before any treatment. Median follow-up was 24 months, ranging from one to 67 months.
A final diagnosis of bone marrow involvement was made if the biopsy was positive, or if the positive PET/CT scan was confirmed by a guided biopsy, by targeted MRI or, after chemotherapy, by the concomitant disappearance of focal bone marrow uptake and uptake in other lymphoma lesions on 18F-FDG PET/CT reassessment. Progression-free survival and overall survival were then analyzed.
The results showed that 33 patients were considered to have bone marrow involvement, eight of whom were positive according to the biopsy. Thirty-two were positive according to the PET/CT scan.
The 18F-FDG PET/CT was more sensitive (94 percent versus 24 percent), showed a higher negative predictive value (98 percent versus 80 percent), and was more accurate (98 percent versus 81 percent) than was the biopsy. Twenty-nine patients (22 percent) experienced recurrence or disease progression during follow-up and 20 patients died (15 percent).
Among the 26 patients with positive 18F-FDG PET/CT results and negative biopsy results, 11 were upstaged to stage IV by PET/CT, which changed their treatment plans. 18F-FDG PET/CT was also determined to be an independent predictor of progression-free survival.
The researchers concluded that bone marrow involvement assessed with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification in newly diagnosed DLBCL than does bone marrow biopsy.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Enhanced Mobile CT System with High-Resolution Photon-Counting Technology
July 15th 2024Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.